Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. - sprookjes - yvandenbroek - TriplyDB

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.

http://www.wikidata.org/entity/Q35524250

about

Update on rational targeted therapy in AML Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?Cancer's Achilles' Heel: Apoptosis and Necroptosis to the Rescue IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives Cholangiocarcinoma: Current Knowledge and New Developments Metabolic consequences of oncogenic IDH mutations 2-Hydoxyglutarate: D/Riving Pathology in gLiomaS Acid ceramidase is upregulated in AML and represents a novel therapeutic target.2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data.The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis.2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling.Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation.Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.Down-Regulation of MicroRNA-133b Suppresses Apoptosis of Lens Epithelial Cell by Up-Regulating BCL2L2 in Age-Related Cataracts.Isocitrate dehydrogenase mutations in myeloid malignancies.Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.Clonal evolution of preleukemic hematopoietic stem cells in acute myeloid leukemia Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification.Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies.Acute myeloid leukemia--major progress over four decades and glimpses into the future.Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Emerging therapeutic drugs for AML.Targeting cancer cell mitochondria as a therapeutic approach: recent updates.Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?Bcl-2 proteins in development, health, and disease of the hematopoietic system.The cancer epigenome: Concepts, challenges, and therapeutic opportunities.

P2860

Q26766152-14C33E5C-DD15-4A49-9367-3B351DE0A687 Q26776393-148B9A3C-FDC0-4228-BFD2-786D93CC93F4 Q26781271-540A5364-E8D2-46CA-A666-4F7622AFE3C9 Q28066868-49FDA488-1960-46A4-A9FF-CA26761543FC Q28066926-71E373C4-3FAE-4E0C-B033-E37F3FA34F1B Q28076098-DAA2BFF6-C0E2-4796-8757-40F9C15B541F Q28082949-2AC88A91-E573-46F2-8115-A6FE1AE32314 Q28087807-476BA5F8-349A-4D92-9185-510499ACCEE4 Q30275460-FBADE6BB-1826-4807-A4ED-AF29EBFE669E Q33698756-F0C46B00-DE6B-47BC-A919-4FECCFD15908 Q33702409-450A0FEC-A159-4BB5-9F64-206DC613674E Q33763540-8A174D3E-D754-4087-A877-CA17A230C3BF Q33766729-992C4093-18D8-472C-8EC1-82893AA6A3F9 Q33796552-1ECB0BDF-F4E4-488F-A384-9D908539D30B Q34543038-0A012050-A6CD-4389-B778-1C9E9C7736BE Q36144842-27BE28BF-164D-490A-BF6C-4FEB7984D969 Q36284637-266FD27F-B5D6-4DCD-B8D8-697F9FDD5550 Q36328206-E1F38AF6-61F3-4890-862C-1777AA3D563F Q36337587-75C95B51-022C-4194-8D9B-7A0FF1D01ECA Q36352394-78D13DBA-323F-458C-B50A-74DF5E734001 Q36767447-DA39FD1A-BADE-4FDF-A907-20341110FC1E Q36805635-FEB40081-AF06-4A4E-8641-64B56169A264 Q37391671-658785F1-4798-4AE2-9D5C-C608C6982B74 Q37625630-32D1268E-C79E-4F4F-A87D-018C8991A82C Q37632016-80FCAF40-B31D-4562-BE28-792F56271501 Q37684619-509E3CE6-F665-4518-B2AF-9F8975DBB2EC Q38375735-5EAA1C95-2D83-4D50-AC72-CE096F8BBF66 Q38428692-934C6A2A-538C-49F0-BFEB-B78B6F62F26E Q38604032-ED6F4C99-B068-4A30-8B06-59C09D8FFD9D Q38608903-31DDF550-BC72-4FE0-9A6B-B3A3C5988B1A Q38637652-6CCB9818-441A-4416-9204-052633B0AF7F Q38644941-C2975A0B-BEA8-4836-9346-E51B181CFC06 Q38656763-70A41D20-FE40-4453-8346-A32338156622 Q38664735-2337E6B9-ADC3-4EEB-9892-F0214E5A2221 Q38667491-860308A5-E5DB-460E-A13B-C635748FD2A3 Q38668524-BE9FD04B-5695-43C5-B2A1-8A4E161ADCE2 Q38703904-29B4CBB9-C71D-4EAC-9A88-4F0704A9727B Q38715325-6CC47F59-0CF2-4739-AECC-A0354E637C66 Q38735628-226BD116-CF5B-4925-A366-1026F86F74B7 Q38743881-3C9BAA49-062A-4694-A8CB-8F568FD062D1

P2860

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.

http://www.wikidata.org/entity/Q35524250

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Isocitrate dehydrogenase 1 and ...... nce in acute myeloid leukemia.

@ast

Isocitrate dehydrogenase 1 and ...... nce in acute myeloid leukemia.

@en

type

label

Isocitrate dehydrogenase 1 and ...... nce in acute myeloid leukemia.

@ast

Isocitrate dehydrogenase 1 and ...... nce in acute myeloid leukemia.

@en

prefLabel

Isocitrate dehydrogenase 1 and ...... nce in acute myeloid leukemia.

@ast

Isocitrate dehydrogenase 1 and ...... nce in acute myeloid leukemia.

@en

P1433

Q35524250-F0047B7E-936A-42B8-93E4-433D3E99C5D1

P1476

Q35524250-67E387A5-7014-4770-8552-DA10E8755814

P2093

Q35524250-018B38ED-BA80-4AE2-AA28-51792C61C8A1

Q35524250-19478113-5C8B-4175-975F-56E5233F549B

Q35524250-1DED1E1D-6991-41BE-AF87-B0FB27987669

Q35524250-4E58A153-57EA-41C9-B648-4554211C5B9C

Q35524250-5003FB03-02E3-4540-847E-66860709CA48

Q35524250-686F543D-B843-437C-8FD4-DA9D0F6A4EBB

Q35524250-95C9F55B-AE7E-41F4-B2C0-D1257A21F977

Q35524250-C5B5AFE5-29BE-427C-9460-4255FC870B12

Q35524250-E790AB77-E606-4A5A-9888-013548440A0F

Q35524250-F1BA0DE6-92B8-4850-B5AB-EF5CC7270166

P2860

Q35524250-0AABA3A8-F971-4815-9367-018509A68FFF

Q35524250-0E37ADCB-F4D9-4A9D-B53F-31E84207DB33

Q35524250-10BF0855-C886-4A9E-AD8B-F67678C3ECE7

Q35524250-15043F12-56DB-40AC-9663-75EF343E816D

Q35524250-150DC225-38CA-4F50-8D24-AF40AF95A08D

Q35524250-1597BC34-27BC-4F78-AA2B-66708C73DCB4

Q35524250-17BC8091-BEEC-43CF-B63D-AB5AD62357CF

Q35524250-279C78FD-64EA-4E0F-B6E6-909E6BC132EF

Q35524250-306D5797-285D-4C92-8A8F-B32393F04794

Q35524250-331C137B-16A9-4098-8FC1-65010DDC4413

P2888

Q35524250-D185FCF9-F2A8-4FE7-AA4D-64B0DE2B56AC

P304

Q35524250-E9B86FEC-59E3-456F-A1B7-E13CC767A428

P31

Q35524250-4B4E0DDF-3798-4469-8F59-22A4910547B9

P356

Q35524250-92B80D57-41EE-4DF0-9A47-3E6B20BB7C5E

P407

Q35524250-1C974395-FB91-474A-9181-DCA98E473820

P433

Q35524250-544C177B-CABA-4823-A2BD-7D69FDA3FA9E

P478

Q35524250-3693A03E-8ED0-4D1F-9EC2-8DF398DE4A93

P577

Q35524250-39CCCA8E-E3F1-4672-B789-EED797D5E247

P698

Q35524250-039482AD-7FAE-4390-BC9E-00632A633396

P921

Q35524250-40E227A3-4852-4CCC-AFF6-D5FFB0C47153

P932

Q35524250-4B54106A-346E-4B85-9BED-7F9C8F33C1B3

P356

P1433

Nature Medicine

P1476

Isocitrate dehydrogenase 1 and ...... nce in acute myeloid leukemia.

@en

P2093

Bruno C Medeiros

http://www.w3.org/2001/XMLSchema#string

Daniel Thomas

http://www.w3.org/2001/XMLSchema#string

David A Tyvoll

http://www.w3.org/2001/XMLSchema#string

Feifei Zhao

http://www.w3.org/2001/XMLSchema#string

M Ryan Corces-Zimmerman

http://www.w3.org/2001/XMLSchema#string

Ravindra Majeti

http://www.w3.org/2001/XMLSchema#string

Seethu Xavy

http://www.w3.org/2001/XMLSchema#string

Steven M Chan

http://www.w3.org/2001/XMLSchema#string

Suchita Rastogi

http://www.w3.org/2001/XMLSchema#string

Wan-Jen Hong

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

Recurring mutations found by sequencing an acute myeloid leukemia genome

An integrated genomic analysis of human glioblastoma multiforme

IDH1 and IDH2 mutations in gliomas

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

P2888

P304

178-184

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.3788

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25599133

http://www.w3.org/2001/XMLSchema#string

P921

P932

4406275

http://www.w3.org/2001/XMLSchema#string